Abstract:Immunoglobulin A (IgA) vasculitis (IgAV, also known as Henoch-Schoenlein purpura, HSP) is the most common vasculitis of childhood. It usually presents with a simple, self-limiting disease course; however, a small subset of patients may develop kidney involvement (IgAV-N) which occurs 4-12 weeks after disease onset and is the biggest contributor to long-term morbidity. Treatment currently targets patients with established kidney involvement; however; there is a desire to work towards early prevention of inflammation during the window of opportunity between disease presentation and onset of significant nephritis. There are no clinical trials evaluating drugs which may prevent or halt the progression of nephritis in children with IgAV apart from the early use of corticosteroids which have no benefit. This article summarises the latest scientific evidence and clinical trials that support potential therapeutic targets for IgAV-N that are currently being developed based on the evolving understanding of the pathophysiology of IgAV-N. These span the mucosal immunity, B-cell and T-cell modulation, RAAS inhibition, and regulation of complement pathways, amongst others. Novel drugs that may be considered for use in early nephritis include TRF-budesonide; B-cell inhibiting agents including belimumab, telitacicept, blisibimod, VIS649, and BION-1301; B-cell depleting agents such as rituximab, ofatumumab, and bortezomib; sparsentan; angiotensin converting enzyme inhibitors (ACE-Is); and complement pathway inhibitors including avacopan, iptacopan, and narsoplimab. Further clinical trials, as well as pre-clinical scientific studies, are needed to identify mechanistic pathways as there may be an opportunity to prevent nephritis in this condition. Key Points • Kidney involvement is the main cause of long-term morbidity and mortality in IgA vasculitis despite the current treatment recommendations. • The evolving understanding of the pathophysiology of IgA vasculitis is allowing exploration of novel treatment options which target underlying immune pathways. • Novel treatments currently being trialled in IgA nephropathy may have benefit in IgA vasculitis due to the similarities in the underlying pathophysiology, such as TRF-budesonide, B-cell modulators, and complement inhibitors. • Further studies, including clinical trials of novel drugs, are urgently needed to improve the long-term outcomes for children with IgA vasculitis nephritis.

A Review of the Pathogenesis of IgA Vasculitis Nephritis in Children

IgA Vasculitis:A Review on Diagnosis and Management

Pathogenesis of IgA Vasculitis: An Up-To-Date Review

Progress in Pathogenesis of Immunoglobin A Nephropathy

Childhood IgA Vasculitis (Henoch Schonlein Purpura)—Advances and Knowledge Gaps

Diagnosis and Treatment of IgA Nephropathy and IgA Vasculitis Nephritis in Chinese Children

Navigating Adult-Onset IgA Vasculitis-Associated Nephritis

Diagnostic and Management Strategies of IgA Vasculitis Nephritis/Henoch-Schönlein Purpura Nephritis in Pediatric Patients: Current Perspectives

Clinicopathological features and prognosis of IgA vasculitis nephritis with nephrotic-range proteinuria in children

Analysis of clinical pathology of the IgA nephropathy and purpura nephritis in children from the perspective of IgA vasculitis

IgA vasculitis with nephritis: an overview of the pathogenesis and clinical characteristic

Venous Sinus Thrombosis in a Case of Immunoglobulin A Vasculitis and a Systemic Review of Literature

IPNA Clinical Practice Recommendations for the Diagnosis and Management of Children with IgA Nephropathy and IgA Vasculitis Nephritis

A narrative review of potential drug treatments for nephritis in children with IgA vasculitis (HSP)

Henoch-Schönlein Purpura (IgA Vasculitis): Rapid Evidence Review

Clinical characteristics and risk factors for kidney involvement in children with immunoglobulin A vasculitis

Comparative study on clinicopathological features and prognosis of IgA vasculitis nephritis and IgA nephropathy in children

A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and Future

Clinicopathological Features of Antineutrophil Cytoplasmic Antibodies Associated Vasculitis with Glomerular IgA Deposits

Risk factors associated with IgA vasculitis with nephritis (Henoch–Schönlein purpura nephritis) progressing to unfavorable outcomes: A meta-analysis

Individualized medication based on pharmacogenomics and treatment progress in children with IgAV nephritis